Buspirone as a Candidate Medication for Methamphetamine Abuse
Information source: University of Kentucky
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Methamphetamine Dependence; Methamphetamine Abuse
Intervention: Methamphetamine (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: University of Kentucky Overall contact: Craig R Rush, Ph.D., Phone: 859-257-5388, Email: crush2@email.uky.edu
Summary
Methamphetamine use disorders are an unrelenting public health concern. Intensive research
efforts have yielded behavioral interventions that reduce methamphetamine use, however,
these interventions are not universally effective and treatment effects diminish over time.
Development of a pharmacotherapy that enhances the efficacy of these interventions is a
priority for the National Institute on Drug Abuse. This study proposes to determine the
impact of buspirone maintenance on self-administration of methamphetamine. These preliminary
data will be used to support further research developing buspirone as a pharmacotherapy for
methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate
the reinforcing effects of methamphetamine.
Clinical Details
Official title: Buspirone as a Candidate Medication for Methamphetamine Abuse
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: Reinforcing Effects of Methamphetamine During Buspirone TreatmentReinforcing Effects of Methamphetamine During Placebo Treatment
Secondary outcome: Subjective EffectsPhysiological and Side Effects
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Lifetime methamphetamine use
Exclusion Criteria:
- Abnormal screening outcome (e. g., ECG, blood chemistry result) that study physicians
deem clinically significant
- Current or past histories of substance abuse or dependence that are deemed by the
study physicians to interfere with study completion
- History of serious physical disease, current physical disease, impaired
cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure
or current or past histories of serious psychiatric disorder that in the opinion of
the study physician would interfere with study participation will be excluded from
participation
- Females not currently using effective birth control
- Contraindications to methamphetamine or buspirone
Locations and Contacts
Craig R Rush, Ph.D., Phone: 859-257-5388, Email: crush2@email.uky.edu
University of Kentucky Medical Center, Lexington, Kentucky 40536, United States; Recruiting William W Stoops, Ph.D., Phone: 859-257-5388, Email: william.stoops@uky.edu Craig R Rush, Ph.D., Principal Investigator
Additional Information
Starting date: April 2013
Last updated: May 11, 2015
|